Carmenta Bioscience, Inc.

Carmenta Bioscience, Inc. develops innovative healthcare solutions focused on advancing precision medicine through cutting-edge diagnostic technologies. Carmenta Bioscience, Inc. specializes in developing diagnostic solutions aimed at enhancing precision medicine.

Founded in 2012 in Palo Alto, US, the company underwent a significant change when it was acquired by Progenity in April 2015. The firm has completed 2 deals and raised a total of USD 2. 00 mn through its Series A funding round, with the latest funding round led by Life Science Angels, Inc. The current company valuation stands at USD 4.

136 mn. Carmenta Bioscience, Inc. specializes in innovative diagnostic technology solutions designed to enhance operational efficiency in healthcare. Their core products include advanced diagnostic systems that support precision medicine, intended for healthcare providers looking to optimize patient care and improve clinical outcomes.

End users of these technologies typically include healthcare professionals and laboratory technicians, enabling them to analyze genetic data effectively. The company targets markets primarily in North America and Europe, focusing on healthcare institutions seeking to leverage technology for improved patient diagnostics. The company generates revenue through a combination of direct sales and partnerships with healthcare providers, enabling clients to access its diagnostic solutions. This model allows for a consistent cash flow while facilitating scalability based on the needs of healthcare institutions.

Clients engage through structured pricing tiers that accommodate various levels of service, ensuring flexibility in usage. Collaborations with healthcare providers enhance the company’s distribution capabilities, further driving recurring revenue from its diagnostic solutions. Carmenta Bioscience, Inc. is planning to expand its product offerings with new diagnostic solutions expected to launch by late 2016, specifically targeting advancements in genetic testing.

The company is also looking to penetrate new markets in Asia and South America by 2017. Funding from the latest Series A round will be utilized to support the development of these new products and to facilitate market entry strategies in these regions. The acquisition by Progenity also opens avenues for further innovation and resource access to enhance their operational capabilities.